TransMedics Group Inc (HAM:8T8) Stock Price, Trades & News

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.54
Equity-to-Asset	0.34
Debt-to-Equity	1.75
Debt-to-EBITDA	6.18
Interest Coverage	5.4
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.37	Distress Grey Safe
Beneish M-Score	-1.32	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	67.8
	3-Year Book Growth Rate	33.3
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	26.46
	Future 3-5Y Total Revenue Growth Rate Estimate	18.96

Momentum Rank

5/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	58.65
	9-Day RSI	57.39
	14-Day RSI	53.36
	3-1 Month Momentum %	-33.97
	6-1 Month Momentum %	-45.72

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	6.74
	Quick Ratio	6.19
	Cash Ratio	5.02
	Days Inventory	63.28
	Days Sales Outstanding	57.7
	Days Payable	15.1

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-2.2
	Shareholder Yield %	-3.69

Profitability Rank

3/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	59.09
	Operating Margin %	14.85
	Net Margin %	27.04
	EBITDA Margin %	21.98
	FCF Margin %	23.79
	OCF Margin %	34.64
	ROE %	45.08
	ROA %	16.6
	ROIC %	17.26
	3-Year ROIIC %	30.91
	ROC (Joel Greenblatt) %	21.64
	ROCE %	11.12
	Years of Profitability over Past 10-Year	2
	Moat Score	6
	Tariff Resilience Score	5

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	15.55
	Forward PE Ratio	38.15
	PE Ratio without NRI	15.61
	Price-to-Owner-Earnings	12.73
	PS Ratio	4.24
	PB Ratio	4.79
	Price-to-Tangible-Book	4.9
	Price-to-Free-Cash-Flow	18.58
	Price-to-Operating-Cash-Flow	12.47
	EV-to-EBIT	25.9
	EV-to-EBITDA	19.8
	EV-to-Forward-EBITDA	13.72
	EV-to-Revenue	4.35
	EV-to-Forward-Revenue	3.78
	EV-to-FCF	18.28
	Price-to-GF-Value	0.41
	Price-to-Graham-Number	1.84
	Earnings Yield (Greenblatt) %	3.86
	FCF Yield %	6.4

Financials (Next Earnings Date:2026-07-30 Est.)

Annual Quarterly TTM

HAM:8T8's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

TransMedics Group Inc Executives

Details

GF Value™: €162.08

HAM:8T8

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 3 Severe warning signs with 8T8. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	546.721
	EPS (TTM) (€)	3.77
	Beta	-
	3-Year Sharpe Ratio	-
	3-Year Sortino Ratio	-
	Volatility %	-
	14-Day RSI	53.36
	14-Day ATR (€)	1.920475
	20-Day SMA (€)	62.981
	12-1 Month Momentum %	-
	52-Week Range (€)	52.7 - 130.2
	Shares Outstanding (Mil)	34.56

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	6
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

TransMedics Group Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

TransMedics Group Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-10-29 16:30	In 122 days
Third quarter earnings results for 2026	2026-10-29	In 121 days
Second quarter earnings conference call for 2026	2026-07-30 16:30	In 31 days
Second quarter earnings results for 2026	2026-07-30	In 30 days
William Blair 46th Annual Growth Stock Conference	2026-06-02 14:20	57.02 (+0.00%)
General meeting for 2026	2026-05-20 08:00	52.70 (+0.00%)
First quarter earnings conference call for 2026	2026-05-05 16:30	83.70 (+0.00%)
First quarter earnings results for 2026	2026-05-05	83.70 (+0.00%)
Oppenheimer 36th Annual Healthcare MedTech & Services Conference	2026-03-16 10:00	105.35 (+0.00%)
TD Cowen 46th Annual Health Care Conference	2026-03-02 13:50	113.05 (+0.00%)

Show

Entries

TransMedics Group Inc Frequently Asked Questions

What is TransMedics Group Inc(HAM:8T8)'s stock price today?

The current price of HAM:8T8 is €66.68. The 52 week high of HAM:8T8 is €130.20 and 52 week low is €52.70.

When is next earnings date of TransMedics Group Inc(HAM:8T8)?

The next earnings date of TransMedics Group Inc(HAM:8T8) is 2026-07-30 Est..

Does TransMedics Group Inc(HAM:8T8) pay dividends? If so, how much?

TransMedics Group Inc(HAM:8T8) does not pay dividend.

Press Release

	Subject	Date
	TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	2026-05-21
	TransMedics to Present at the William Blair 46th Annual Growth Stock Conference	2026-05-19
	TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH	2026-04-29
	TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting	2026-04-23
	TransMedics to Report First Quarter 2026 Financial Results on May 5, 2026	2026-04-21
	TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results	2026-02-27
	TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results	2026-02-24
	TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	2026-02-20
	TransMedics to Present at Upcoming March Investor Conferences	2026-02-17
	TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026	2026-02-10

10/Page

Articles on TransMedics Group Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.